Vivimed Labs Limited
Vivimed Labs Ltd is primarily engaged in the business of APIs, CDMO, Finished Dosage Formulation, Specialty Chemicals and retail branded formulation manufacturing.
What Vivimed files
- Others28
- Important21
- Updates11
- Board Meeting6
- Results3
Vivimed Labs clarified procedural issues in its financial results filing. These include a signing formality, a minor technical delay in submission, and XBRL discrepancies being resolved. The company confirms these do not alter the previously disclosed financial figures.
Vivimed Labs Ltd. has announced a board meeting to discuss the audited financial results for the quarter and year ended 31 March 2023. The company reported a significant liquidity crisis, resulting in defaults on payments to banks totaling ₹3,762.80 million. This situation was exacerbated by post-COVID-19 operational challenges. Additionally, the...
Vivimed Labs Limited has reported its financial results for the quarter and nine months ended December 31, 2024. The company generated total revenue of ₹908.09 crore, with a profit before tax of ₹(263.61) crore. Notably, Vivimed has defaulted on loan repayments totaling ₹3,746.40 crore, classified as non-performing assets (NPAs) due...